immunotherapy

Johns Hopkins Kimmel Cancer Center's perioperative immunotherapy trials show 80% surgical completion and extended survival for mesothelioma patients. Learn who qualifies.

NCI awards $10.7M to Penn for CAR T-cell therapy targeting mesothelin in mesothelioma. Explore clinical data, eligibility, and breakthrough cell immunotherapy.

Mayo Clinic's #1-ranked mesothelioma program delivers multidisciplinary treatment with access to clinical trials across Rochester, Phoenix, and Jacksonville locations.

FDA-approved immunotherapy drugs Keytruda and Opdivo are transforming mesothelioma treatment. Learn how checkpoint inhibitors work, who qualifies, and what results patients are seeing in 2026.

Explore the best mesothelioma treatment options in 2026, including 56+ active clinical trials, immunotherapy combinations, and targeted therapies that are quadrupling survival rates.